Loading stock data…
$10.49-0.52 (-4.72%)
Sutro Biopharma, Inc.
Sutro Biopharma, Inc. in the Healthcare sector is trading at $10.50 with a market capitalization of $317M. Wall Street consensus targets $47.23 (13 analysts), implying a +349.8% move over the next 12 months. The stock is currently near its 52-week low of $7.15, remaining 54.6% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 16 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $9.84M↓ | $14.52M↑ | $11.65M↑ | $9.69M↓ | $63.74M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$29.69M↓ | -$29.61M↑ | -$33.66M↑ | -$38.90M↓ | $15.08M |
| Net Income | -$38.53M↓ | -$38.48M↑ | -$46.76M↑ | -$56.86M↓ | -$11.50M |
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conju...